The international surgical journal with global reach

Adjuvant 131I-metuximab for hepatocellular carcinoma after liver resection: a randomised, controlled, multicentre, open-label, phase 2 trial. Lancet Gastroenterol Hepatol 2020; 5: 548-560.

Published: 17th November 2020

Authors: Li J, Xing J, Yang Y, Liu J, Wang W, Xia Y et al.

Conclusion

Some 156 patients were included. After median follow-up of 55.9 months, relapse-free survival was 43.4 per cent after active treatment versus 21.7 per cent in controls (hazard ratio 0.49, 95 per cent confidence interval 0.34 to 0.72, P=0.0031).

Pubmed Link